We also used BRCA1-deficient ovarian cancer cell line UWB1 75,76 and showed that acquired Olaparib resistance of UWB1 cells upon 53BP1 depletion can be reverted by inhibiting PIF1 (Supplementary Figure 11b). Here, PIF1 is linked to ovarian carcinoma.